TARIFFS LATEST

US, China to slash tariffs for 90 days

Canadian Sec - Free Realtime Quote CAD

Biomark Diagnostics Inc. (BUX.CN)

0.2800

0.0000

(0.00%)

As of May 8 at 9:37:56 AM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for BUX.CN

BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

BioMark Announces the Final Closing of Oversubscribed Private Placement

BioMark Announces the Final Closing of Oversubscribed Private Placement

BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform

BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform

BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection

BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York

The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay

The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay

AVCR.V Avricore Health Inc.

0.0500

0.00%

IZO.CN Izotropic Corporation

0.2800

0.00%

EDT.TO Spectral Medical Inc.

0.8500

-3.41%

EXAS Exact Sciences Corporation

52.36

+1.40%